Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 1.00 |
| ▸ | GRM5 | P41594 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15735672 | 0.84 | PDE10A (0.72) | PDE10AGRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9752587 | 0.76 | PDE10A (0.60) | PDE10ANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7352490 | 0.76 | PDE10A (0.60) | PDE10ANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7377231 | 0.76 | PDE10A (0.60) | PDE10ANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL9297972 | 0.74 | PDE10A (0.57) | PDE10ANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7378515 | 0.74 | TGFBR1 (0.65) | PDE10ASMN1; SMN2KDM4ECYP3A4HPGD | |
| SCHEMBL7343693 | 0.74 | TGFBR1 (0.65) | PDE10ASMN1; SMN2KDM4ECYP3A4HPGD | |
| SCHEMBL9199906 | 0.74 | PDE10A (0.57) | PDE10ANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7381132 | 0.73 | TGFBR1 (0.67) | PDE10ANPC1RAB9ASMN1; SMN2KDM4E | |
| Bromide SCHEMBL9699922 | 0.73 | PDE10A (0.56) | PDE10ANPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | claimed |
| EP-2922842-B1 | INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC (US) | 2017-06-14 | — | — | EP | claimed |
| CN-104995183-A | Novel phosphodiesterase type 10A inhibitor compounds | ABBVIE INC | 2015-10-21 | — | — | CN | claimed |
| EP-2922842-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Inc. (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014079995-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2014-05-30 | — | — | WO | claimed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | claimed |
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| CN-115484938-A | Composition and use thereof | 博善人工智能剑桥有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9790203-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2922842-B1 | INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC (US) | 2017-06-14 | — | — | EP | disclosed |
| CN-104995183-A | Novel phosphodiesterase type 10A inhibitor compounds | ABBVIE INC | 2015-10-21 | — | — | CN | disclosed |
| EP-2922842-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079995-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | PDE10A 17/4885GRM5 2399/4885NPC1 2521/4885 |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | PDE10A 5/4885GRM5 1400/4885NPC1 3911/4885 |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | PDE10A 17/4885GRM5 2464/4885NPC1 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.